- Home
- COKE vs PRAX Comparison
COKE vs PRAX Comparison
Compare COKE & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COKE | PRAX |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 8.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | COKE | PRAX |
|---|---|---|
| Price | $165.42 | $331.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $519.60 |
| AVG Volume (30 Days) | 394.6K | ★ 540.8K |
| Earning Date | 02-18-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | ★ 22.14 | N/A |
| EPS | ★ 7.03 | N/A |
| Revenue | ★ $7,070,308,000.00 | $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29,535.93 |
| P/E Ratio | $22.64 | ★ N/A |
| Revenue Growth | 4.22 | ★ 364.98 |
| 52 Week Low | $105.21 | $26.70 |
| 52 Week High | $169.49 | $328.60 |
Technical Indicators
Market Signals| Indicator | COKE | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 65.91 | 64.92 |
| Support Level | $152.94 | $302.00 |
| Resistance Level | $159.75 | $328.60 |
| Average True Range (ATR) | 4.57 | 16.86 |
| MACD | 1.43 | -0.21 |
| Stochastic Oscillator | 97.63 | 94.43 |
Price Performance
Historical ComparisonAbout COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc distributes, markets and manufactures nonalcoholic beverages. It offer a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages and the Company's principal sparkling beverage is Coca Cola. Still beverages include energy products and noncarbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices and sports drinks. The Company has three operating segments: Nonalcoholic Beverages, All Other and Eliminations. key revenue is generated from Nonalcoholic Beverages.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.